Efficacy of RPh201 Applied Topically for the Treatment of Hard to Heal Chronic Ulcerated Wounds
A PRELIMINARY OPEN CLINICAL STUDY, TO ASSESS THE SAFETY AND EFFICACY OF RPh201 APPLIED TOPICALLY FOR THE TREATMENT OF HARD TO HEAL CHRONIC ULCERATED WOUNDS
Sponsor: Regenera Pharma Ltd
Terminated
Due to slow recruitment
Other terminated trials from Regenera Pharma Ltd
More terminations from Regenera Pharma Ltd
Other Chronic Wound trials with similar outcome
A PHASE1/PHASE2 clinical study on Chronic Wound, this trial is terminated or withdrawn. The trial is conducted by Regenera Pharma Ltd and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Oct 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Terminated PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Regenera Pharma Ltd
- TransCom Global Ltd. (CRO)
For direct contact, visit the study record on ClinicalTrials.gov .